SCHEMBL5765301

SCHEMBL5765301

c1cc2nonc2cc1CCCC1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 4/20 0.48
KCNH2 Q12809 4/20 0.48
HRH3 Q9Y5N1 2/20 0.43
NMT1 P30419 5/20 0.40
SLC6A4 P31645 1/20 0.39
ITGB3 P05106 2/20 0.38
ITGA2B P08514 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KHK P50053 1/20 0.36
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5764095 0.99 KCNJ1 (0.47) KCNJ1KCNH2HRH3NMT1SLC6A4
Hydrochloric Acid SCHEMBL18280055 0.81 GBA1 (0.47) KCNJ1KCNH2HRH3SLC6A4ALDH1A1
SCHEMBL7493812 0.74 HRH3 (0.43) HRH3NMT1SLC6A4ITGB3ITGA2B
SCHEMBL11401683 0.74 PRMT5 (0.58) KCNH2HRH3NMT1SLC6A4ITGB3
SCHEMBL17484487 0.73 KCNJ1 (0.42) KCNJ1KCNH2HRH3ALDH1A1ALOX15
SCHEMBL7493566 0.73 SLC6A4 (0.46) HRH3NMT1SLC6A4ALDH1A1
Hydrochloric Acid SCHEMBL5763270 0.72 HRH3 (0.42) HRH3NMT1SLC6A4ITGB3ITGA2B
Hydrochloric Acid SCHEMBL5765723 0.72 SLC6A4 (0.45) HRH3NMT1SLC6A4ALDH1A1
SCHEMBL11338421 0.72 SLC6A4 (0.40) KCNH2HRH3NMT1SLC6A4ITGB3
SCHEMBL297781 0.71 KCNH2 (0.80) KCNJ1KCNH2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192133-B1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2006-11-02 EP disclosed
US-6593346-B2 Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. MERCK & CO. INC. 2003-07-15 US disclosed
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-08-29 US disclosed
EP-1192133-A1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2002-04-03 EP disclosed
US-6358979-B1 FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS MERCK & CO., INC. 2002-03-19 US disclosed
WO-2000076972-A1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity CCR1, CCR3, CCR5 KCNJ1 4593/4885KCNH2 3461/4885HRH3 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.